Drugs / LY2189102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00380744 | Nov 2005 → Nov 2007 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00942188 | Jun 2009 → Nov 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2189102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00380744 ↗ |
| Action | Inhibit | “anti-IL-1β” PMID 24912797 ↗ Jun 2014 |
| Modality | Monoclonal antibody | “LY2189102, a high affinity anti-IL-1β humanized monoclonal immunoglobulin G4” PMID 24912797 ↗ Jun 2014 |
| Route | Subcutaneous | “Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.” NCT00942188 ↗ |
| Target | IL1B | “anti-IL-1β” PMID 24912797 ↗ Jun 2014 |